Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation.

OBJECTIVE Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of >10 yr. METHODS Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. RESULTS It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (</=7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. CONCLUSIONS After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

[1]  D. Tuffanelli,et al.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES. , 1964, JAMA.

[2]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[3]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[4]  E. Dubois.  The effect of the L. E. cell test on the clinical picture of systemic lupus erythematosus. , 1953, Annals of internal medicine.

[5]  M. Merrell,et al.  Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. , 1955, Journal of chronic diseases.

[6]  D. Gladman,et al.  Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. , 1996, Clinical and experimental rheumatology.

[7]  J. Nossent,et al.  Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. , 1989, Annals of the rheumatic diseases.

[8]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[9]  E. Dubois.  Systemic lupus erythematosus: recent advances in its diagnosis and treatment. , 1956, Annals of internal medicine.

[10]  S. Studenski,et al.  Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. , 1995, Arthritis and rheumatism.

[11]  D. Alarcón-Segovia,et al.  Remission of Systemic Lupus Erythematosus , 1996 .

[12]  D. Gladman,et al.  Morbidity in systemic lupus erythematosus. , 1987, The Journal of rheumatology. Supplement.

[13]  C. Bombardier,et al.  Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. , 1992, The Journal of rheumatology.

[14]  D. Estes,et al.  THE NATURAL HISTORY OF SYSTEMIC LUPUS ERYTHEMATOSUS BY PROSPECTIVE ANALYSIS , 1971, Medicine.

[15]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[16]  G. Hughes,et al.  Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients , 1993 .

[17]  J. Nossent,et al.  Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. , 1989, Annals of the rheumatic diseases.

[18]  L. Hill.  Systemic Lupus Erythematosus.—II* , 1957 .